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Abstract
As a subunit of mitochondrial complex III, UQCRB plays an important role in complex III 
stability, electron transport, and cellular oxygen sensing. Herein, we report UQCRB function 
regarding angiogenesis in vivo with the zebrafish (Danio rerio). UQCRB knockdown inhibited 
angiogenesis in zebrafish leading to the suppression of VEGF expression. Moreover, the UQCRB-
targeting small molecule terpestacin also inhibited angiogenesis and VEGF levels in zebrafish, 
supporting the role of UQCRB in angiogenesis. Collectively, UQCRB loss of function by either 
genetic and pharmacological means inhibited angiogenesis, indicating that UQCRB plays a key 
role in this process and can be a prognostic marker of angiogenesis- and mitochondria-related 
diseases.
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1. Introduction
The mitochondrion is primary energy source of the cell, bearing five oxidative 
phosphorylation complexes that regulate in ATP synthesis [1]. Of the five complexes, 
complex III is responsible for electron transport, ubisemiquione radical stabilization, and 
cellular oxygen sensing [2]. Notably, complex III deficiency is associated with lactic 
acidosis, hypoglycemia, encelopathy and other human disorders [3]. Recent reports provide 
evidence that deletion of the gene encoding UQCRB (ubiquinol-cytochrome c reductase 
binding protein), a complex III subunit, causes a defect in complex III function, resulting in 
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hypoglycemia and lactic acidosis [4]. Furthermore, two SNPs of UQCRB were found in 
colorectal cancer, implying its potential as a prognostic marker for cancer [5]. Also, 
UQCRB is overexpressed in liver cancer cells, and copy number variation was found in 
cervical cancer and may be used as a cellular marker for cervical cancer diagnosis [6]. Jung 
et al. demonstrated that UQCRB plays a key role in VEGF signaling and regulates 
angiogenesis, and that terpestacin is the small molecule that binds to UQCRB [7]. Given 
these interesting roles, the present paper focuses on mitochondria complex III subunit 
UQCRB, and its possible role in angiogenesis in vivo.
The zebrafish is an ideal animal model for studying vascular development because of its 
tissue transparency and short development time [8,9]. In addition, gene function is readily 
interrogated in this system using morpholino antisense oligonucleotides or pharmacological 
agents [10–13]. Indeed, Tg(fli1a:EGFP)y1 transgenic zebrafish is widely used to visualize 
vasculogenesis and angiogenesis [14,15]. Vasculogenesis is the formation of new blood 
vessels, including those in the dorsal aorta and the posterior cardinal vein of the tail [16]. 
Vasculogenesis is followed by angiogenesis, which is the sprouting and extension of the 
intersegmental vessels (ISVs) from the dorsal aorta. Complete ISVs form the T-branch at the 
most dorsal side of the trunk, known as the dorsal longitudinal anastomotic vessel (DLAV). 
By evaluating the formation of complete ISVs in developing zebrafish, angiogenesis 
inhibition can be easily assessed for small-molecule or morpholino effects.
Herein, we report in vivo functional studies of UQCRB in respect with angiogenesis using 
the zebrafish system. Tg(fli1a:EGFP)y1 zebrafish embryos were used to visualize and 
analyze angiogenesis inhibition by downregulation of UQCRB function. UQCRB activity 
was reduced by knockdown with a uqcrb-MO or a UQCRB-targeting small molecule, 
terpestacin, treatment, leading to the inhibition of blood vessel growth. This is the first 
functional characterization of UQCRB in vivo, providing evidence that UQCRB plays an 
important role in angiogenesis.
2. Materials and methods
2.1. Zebrafish husbandry
Zebrafish were maintained on 14 h light/dark cycle at 28 °C. All experiments involving 
zebrafish were performed according to the National Institute of Health guidelines. Embryos 
were collected and raised in E3 media or ringer’s solution according to standard protocol 
[17].
2.2. Morpholino injection and small molecule treatment
Zebrafish were injected in E3 media or ringer’s solution at the one-cell stage with 1 or 2 ng/
embryo morpholino oligonucleotides (MO). MO was obtained from Gene Tools (Philomath, 
OR) with the following sequence to block 5′ translation of UQCRB: 5′-
GTGCCCTCGCCGCCATTTTTGTTCT-3′. DMSO and terpestacin stock solution (10 
mg/mL in DMSO) were dissolved in ringer’s solution to appropriate concentrations. Final 
volume of compounds did not exceed 1% of the total volume. Embryos were added to the 
solutions at one cell stage.
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Tricaine supplied in E3 media or ringer’s solution (0.6%, w/v) was used to anesthetize the 
embryos for imaging. Anesthesized embryos were immobilized in 0.5% (w/v) low melting 
pointing agarose (Sigma–Aldrich, Saint Louis, MO) on slide glass. Microscopy images of 
zebrafish were taken with Leica S6E.
2.4. RNA isolation, RT-PCR analysis and primer construction
Zebrafish total RNA was isolated with RNeasy Mini kit (Qiagen) according to the 
manufacturer’s protocol or with Trizol (Invitrogen, Carlsbad, CA) followed by precipitation 
with isopropanol, washing with 70% ethanol, and elution with DEPC treated water. Total 
RNA (5 μg) was reversibly transcribed by Molony murine leukemia virus reverse 
transcriptase (Invitrogen, Carlsbad, CA) using Oligo-d(T)15 primer in a final volume of 40 
μL. cDNA mixture (2 μL) was used for PCR amplification of the specific gene with exTaq 
(Takara Bio Inc, Japan). SuperScript III One-Step RT-PCR System with Platinum Taq DNA 
Polymerase kit (Invitrogen, Carlsbad, CA) was applied according to the manufacturer’s 
protocol for terpestacin treated embryos. Primers used for vegfa and β-actin are as follows: 
vegfa forward: CAGCTGTCAAGAGTGCCTACATAC, vegfa reverse: 
CATCAGGGTACTCCTGCTGAATTTC, β-actin forward: CGAGCTGTCTTCCCATCCA, 
β-actin reverse: TCACCAACGTAGCTGTCTTTCTG.
2.5. Statistical analysis
All statistical analyses were calculated with Graphpad Prism (ver. 5.00 for Windows, Graph 
Pad Software, San Diego, CA USA, www.graphpad.com). Results are expressed as mean ± 
standard error (± SEM). Student’s t-tests were used to determine statistical significance 
between control and test groups. ANOVA (Turkey test) was used to determine statistical 
significance between three test groups. A p-valueless than 0.05 was considered statistically 
significant (* indicates p < 0.05, ** indicates p < 0.001, *** indicates p < 0.0001).
3. Results
3.1. Zebrafish angiogenesis is inhibited by UQCRB knockdown
To investigate the biological function of UQCRB in zebrafish, the translation blocker 
morpholino specific to uqcrb (uqcrb-MO) was applied. Uqcrb-MO was injected into 
Tg(fli1a:EGFP)y1 embryos at the one-cell stage to knockdown UQCRB. ISVs were detected 
at 30 h post fertilization (hpf). Uqcrb-MO dose dependently inhibited angiogenesis at 30 hpf 
starting from 1 ng. Two nanograms of uqcrb-MO completely inhibited angiogenic sprouting 
but vasculogenesis was not affected (Fig. 1A). The percentage of angiogenesis-inhibited 
embryos was 55.3% at 1 ng, which increased up to 78.0% at 2 ng (Fig. 1B). Angiogenic 
sprouts and ISVs were examined in UQCRB knockdown embryos starting from 24 to 36 
hpf, the timeframe for angiogenesis in wildtype zebrafish. Normal dorsal aorta was detected 
in all embryos at all timeframes. At 24 hpf, the average number of angiogenic sprouts were 
22 for control, 5.7 for uqcrb-MO 1 ng injected embryos and 1.8 for uqcrb-MO 2 ng injected 
embryos (Fig. 2A). Complete ISVs were not detected at 24 hpf in all embryos. At 30 hpf, an 
average of 19.5 complete ISVs that extended to form the DLAV were assessed in control 
embryos, but none in uqcrb morphants. The number of angiogenic sprouts decreased in a 
Cho et al. Page 3













dose-dependent manner compared to control; an average of 15 and 4.8 sprouts were 
examined in 1 ng and 2 ng uqcrb-MO injected embryos respectively. At 36 hpf, the average 
number of angiogenic sprouts increased to 28.5, 22.7, and 16.3 in control, 1 ng and 2 ng 
uqcrb-MO injected embryos, respectively. However, only three complete ISVs were formed 
in uqcrb-MO injected groups, compared to 25 for control embryos. The lengths of 
angiogenic sprouts were measured at each time frame (Fig. 2B). The average length of 
angiogenic sprouts decreased dose-dependently at all time frames in uqcrb morphants. 
Taken together, UQCRB knockdown with uqcrb-MO inhibits angiogenesis in zebrafish, in 
accordance to previous report with human cell lines tested for angiogenesis in vitro [7].
3.2. Zebrafish uqcrb morphants exhibit defects in morphology
Notably, the morphology of uqcrb-MO injected embryos showed ventral body curvature 
(Fig. 3A) in 55% of the 1 ng injected embryos and 73.4% of 2 ng injected embryos, which 
correlates with angiogenesis inhibition (Fig. 3B). Even with this developmental defect, the 
overall survival rate decreased only 21.3%, from 90% in control to 68.7% in uqcrb-MO 2 ng 
injected embryos (Fig. 3C).
3.3. Zebrafish angiogenesis is inhibited by the UQCRB-targeting small molecule 
terpestacin
Terpestacin is a natural product that inhibits angiogenesis by binding to UQCRB, which was 
reported by Jung et al. [7]. To test the possibility that terpestacin could also inhibit 
angiogenesis in zebrafish, we first compared the amino acid sequence of zebrafish UQCRB 
was compared with that of human UQCRB. UQCRB is highly conserved in human and 
zebrafish, with 72.1% amino acid sequence similarity (Fig. 4A). To investigate the effects of 
terpestacin on zebrafish angiogenesis, Tg(fli1a:EGFP)y1 embryos were cultured in the 
presence of the compound. Terpestacin treatment (20 μM) inhibited angiogenesis at 30 hpf, 
but the development of dorsal aorta was not affected and overall morphology was normal 
(Fig. 4B). Notably, terpestacin treated embryos exhibited high survival rate of 80.2% (Fig. 
4C). The average number of complete ISVs was only 0.5 with terpestacin treatment 
compared to 19.5 in control embryos (Fig. 4D). The number of angiogenic sprouts 
significantly decreased from an average of 23.5 sprouts in control embryos to 15.3 in 
terpestacin-treated embryos (Fig. 4D). The average length of angiogenic sprouts decreased 
54% in terpestacin-treated embryos compared to control (Fig. 4E). Overall, these results 
demonstrate that terpestacin inhibits angiogenesis in zebrafish.
3.4. Vegfa expression is reduced in terpestacin-treated zebrafish or uqcrb morphants
Of many angiogenic factors in angiogenesis signaling, VEGF is one of the important 
cytokine factors involved in UQCRB down-stream signaling. Therefore, vegfa expression 
levels were examined in both UQCRB knocked-down and terpestacin-treated embryos. 
UQCRB knockdown with 2 ng of uqcrb-MO resulted in decrease of overall vegfa expression 
level down to 56% compared to control (Fig. 4F). Likewise, embryos treated with 
terpestacin for 30 hpf resulted in significant decrease of vegfa level compared to control 
(Fig. 4F). Taken together, these results reveal that UQCRB mechanism includes VEGF 
transcription in vivo.
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Mitochondria complex III consists of 11 subunits including UQCRB, which acts in 
cooperation with angiogenic pathways. Loss of UQCRB function reduces angiogenic 
signaling in vitro, yet detailed functional characterization is needed to explain its role in 
biological systems. Therefore, we investigated the possible role of UQCRB in angiogenesis 
with the zebrafish system, resulting in a clearer understanding of UQCRB loss of function in 
relation to angiogenesis. Mitochondria complexes control the general level of oxidative 
phosphorylation, (OXPHOS), by affecting the mitochondrial electron transport chain. In the 
case of complex I inhibition by metform in, angiogenesis is decreased along with VEGF 
levels with metformin treatment [18–20]. However Phoenix et al. reported that metformin 
could also induce angiogenesis through AMPK activation in ERα negative MDA-MB-435 
breast cancer model [21]. Furthermore, complex V inhibition with oligomycin is reported to 
inhibit HIF-1α, the upstream effector of VEGF [22]. Although there were no reports with 
direct angiogenesis inhibition by oligomycin, HIF-1α inhibition in hypoxic tumor cells 
provides evidence to possible angiogenesis inhibition. Likewise, mitochondria complexes 
could affect angiogenesis through OXPHOS regulation [23,24].
Antisense and pharmacological disruption of UQCRB function inhibited angiogenesis in 
zebrafish, but did not affect vasculogenesis. Angiogenesis recovered in both uqcrb 
morphants and terpestacin-treated embryos after 48 hpf, possibly due to the transient or 
incomplete penetrance of these perturbations. Alternatively, there may be distinct temporal 
requirements for UQCRB during angiogenesis or UQCRB may play a supportive but not 
essential role in the sprouting and extension of blood vessels in vivo. We note that uqcrb 
morphants and terpestacin-treated embryos exhibit some phenotypic differences; uqcrb 
morpholinos can induce ventral body curvature while terpestacin causes a more significant 
loss of vegf expression. These differences may be due to the fact that the uqcrb morpholino 
prevents UQCRB expression while terpestacin only inhibits the biological activity of this 
mitochondrial complex III subunit, functionally distinct perturbations that may have 
divergent phenotypic consequences. The antisense oligonucleotide and/or small-molecule 
treatments may also have unanticipated, non-overlapping off-target effects. Finally, UQCRB 
may promote angiogenesis through both VEGF-dependent and VEGF-independent 
mechanisms. Further studies will be necessary to resolve these questions.
To our best knowledge, this is the first report on the functional characterization of UQCRB 
in vivo. UQCRB is involved in diseases related to mitochondria complex III, and in the 
present study UQCRB involvement in angiogenesis was revealed. These results implicate 
that UQCRB could be used in etiologic studies, especially regarding angiogenesis-related 
diseases. Furthermore, UQCRB could be used as a marker for angiogenesis, and drugs that 
specifically target UQCRB could be developed to introduce new therapeutic treatments. 
UQCRB transgenic studies would also provide in-depth evidence for its diverse potential in 
disease and facilitate mechanistic studies of mitochondria and UQCRB.
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Knockdown of UQCRB inhibits zebrafish angiogenesis. (A) Complete ISVs at 30 hpf in 
control embryos. (B) Inhibition of angiogenesis in 1 ng uqcrb-MO injected embryos (n = 30, 
representative image from three independent trials). (C) Inhibition of angiogenesis in 2 ng 
uqcrb-MO injected embryos (n = 30, representative image from three independent trials). 
(D) Dose-dependent inhibition of angiogenesis in uqcrb-MO injected embryos. Quantified 
data are presented as mean ± SEM compared to control (**indicates p < 0.001, ***indicates 
p < 0.0001). Scale bar indicates 100 μm.
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(A) Angiogenic sprouts were detected starting from 24 hpf in control embryos. An average 
of 19.5 complete ISVs was detected in control embryos starting from 30 hpf. Complete ISVs 
were not detected in 1 and 2 ng uqcrb-MO injected embryos until 36 hpf. Only an average 
of three complete ISVs was examined in uqcrb-MO injected embryos (n = 5). (B) 
Angiogenic sprout length showed a great difference between control and dose-dependently 
decreased in uqcrb-MO injected embryos at all time frames. All quantified data are 
presented as mean ± SEM (*indicates p < 0.05, **indicates p < 0.001, ***indicates p < 
0.0001).
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(A) Body curvature morphology was detected in 2 ng uqcrb-MO injected embryos at 24 and 
48 hpf (n = 30, three independent trials). (B) Number of curved embryos increased dose-
dependently in uqcrb-MO injected groups. (C) Survival rates decreased only down to 68.7% 
in 2 ng uqcrb-MO injected embryos. All quantified data are presented as mean ± SEM 
(*indicates p < 0.05). Scale bars indicate 200 μm.
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(A) UQCRB is conserved in human and zebrafish. The amino acid sequence alignment 
shows 72% similarity between human and zebrafish. (H: Homo sapiens, D: Danio rerio) 
Asterisks represent the identical amino acid of two sequences. (B) Terpestacin inhibited 
angiogenesis in zebrafish at 30 hpf. (C) The survival rate for terpestacin treated embryos 
decreased mildly to 80%. (D) Only an average of 0.5 complete ISV was examined in 
terpestacin treated embryos. The average number of angiogenic sprouts decreased to 15.2, 
compared to control embryos which had an average of 23 sprouts. (E) The length of 
angiogenic sprouts in terpestacin treated embryos decreased 47% compared to control. All 
quantified data are presented as mean ± SEM (***indicates p < 0.0001). (F) Vegfa levels 
decreased in uqcrb-MO injected embryos and terpestacin treated embryos at 30 hpf. 
Numbers indicate vegfa expression ratio compared to control (n = 35, three independent 
trials). Scale bar indicates 100 μm.
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